Circulating IGF2BP3 enables risk stratification and predicts treatment response in Ewing sarcoma
A new blood test detecting a cancer protein offers pediatricians an affordable way to better predict outcomes and guide treatment decisions in Ewing sarcoma.
This study demonstrates that plasma IGF2BP3, a RNA-binding oncogenic driver, can be detected via ELISA in a subset (43%) of Ewing sarcoma patients and correlates with tumor tissue expression and poor prognosis, particularly in localized disease. While limited by small sample size and single-center design, the accessible ELISA-based assay offers a promising low-cost addition to risk-adapted therapeutic decision-making for this rare pediatric cancer.
What the study was
- Study design
- Prospective single-center biomarker study with longitudinal analysis
- Population
- Patients with Ewing sarcoma (pediatric rare bone tumor), IRCCS Rizzoli Orthopedic Institute, Italy
- Sample size
- 51
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
Rare pediatric cancer (Ewing sarcoma) with novel circulating protein biomarker for risk stratification. HR of 10.63 for disease-specific survival is striking but confidence interval is wide (1.27–88.62), indicating small sample limitation. ELISA-based approach is accessible and inexpensive. Needs multicenter validation before clinical adoption.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.